Latest other current liabilities for PHAT: $150M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Phathom Pharmaceuticals (PHAT) currently reports a other current liabilities of $150M as of June 2026. That compares with $66M in the prior-year period — up 123.7% year over year. Use the charts on this page to explore Phathom Pharmaceuticals's other current liabilities history and peer comparisons.
Phathom Pharmaceuticals's other current liabilities increased from $66M to $150M — a 123.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Phathom Pharmaceuticals reported $150M in other current liabilities as of June 2026. That compares with $66M in the prior-year period — up 123.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current other current liabilities of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Phathom Pharmaceuticals, and consider following PHAT for alerts when major investors trade the stock.
Phathom Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAT with unrelated industries.